Opportunity Information: Apply for RFA CA 13 501
Apply for RFA CA 13 501
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Limited Competition Adult Brain Tumor Consortium (ABTC) (UM1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.395 Cancer Treatment Research.
- This funding opportunity was created on Jun 19, 2013 and posted on Jun 19, 2013.
- Applicants must submit their applications by Sep 16, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $2,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Only the current awardees of Adult Brain Tumor Consortium funded under RFA CA 08 504 are eligible to apply. Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Limited Competition Adult Brain Tumor Consortium (ABTC) (UM1) funding opportunity (RFA-CA-13-501) is a National Cancer Institute (NCI), National Institutes of Health cooperative agreement designed to continue and strengthen NCI's established clinical trials program focused on adult brain tumors, with a particular emphasis on glioblastoma multiforme (GBM). The intent is not to create a new consortium, but to sustain an existing, NCI-supported clinical trials network that can rapidly evaluate promising anticancer therapies for adults with GBM and related brain tumors. Because this is a cooperative agreement (UM1), the program is structured around substantial NCI involvement in the planning, coordination, and oversight of the work, reflecting the complexity and national importance of conducting early-stage therapeutic trials in this patient population.
A central priority of the announcement is maintaining ABTC's focus on early phase clinical development, specifically Phase I and Phase II trials that test new agents and treatment approaches in adults with GBM. The consortium is expected to identify agents with signs of antitumor activity and to do so in a way that is clinically rigorous, operationally efficient, and well-coordinated across participating sites. In practical terms, this means designing and running trials that can determine safety, dosing, preliminary efficacy, and feasibility, while also supporting the decision-making needed to move the most promising interventions forward in the development pipeline.
In addition to running early-stage trials, the FOA explicitly pushes the consortium to expand and deepen its translational research capabilities. The expectation is that ABTC will go beyond standard clinical endpoints and incorporate studies that clarify how a drug behaves in the body and how it interacts with its intended biological targets. This includes a stronger emphasis on understanding the pharmacokinetics (how the drug is absorbed, distributed, metabolized, and eliminated) and pharmacodynamics (what biological effects the drug produces, including whether it hits the intended target). The FOA highlights the need to characterize drug effects on relevant cellular and molecular targets using appropriate biospecimens, and to integrate those laboratory and biomarker findings with clinical data. The larger goal is to improve understanding of the biological and molecular factors that influence response in GBM, which can help refine patient selection, optimize dosing strategies, and guide rational combination therapies.
This announcement is labeled a limited competition because eligibility is tightly restricted. Only the current awardee(s) of the Adult Brain Tumor Consortium previously funded under RFA-CA-08-504 may apply, and only one award is expected to be made. Foreign institutions are not eligible, and foreign components as defined by NIH policy are not allowed, reinforcing that the supported infrastructure and trial operations must be based in the United States. The opportunity is categorized as discretionary funding under the health-related activity area, with the specific CFDA number listed as 93.395 (Cancer Treatment Research).
From an administrative and funding standpoint, the FOA was posted on June 19, 2013, with an application due date of September 16, 2013, and an archive date of October 17, 2013. The estimated total funding amount is $2,000,000, and the award ceiling is also $2,000,000, with no cost sharing or matching requirement. The funding instrument type is a cooperative agreement, signaling that NCI will play an active partnership role rather than functioning solely as a passive funder.
Overall, the grant opportunity is aimed at ensuring continuity of a specialized national clinical trials consortium dedicated to GBM, while raising expectations for integrated translational science. The ABTC is expected to deliver not only well-run Phase I and II studies that identify promising therapies, but also mechanistic and biomarker-driven insights that show whether drugs reach and affect their targets in patients. By requiring comprehensive PK/PD work and biospecimen-based target analyses linked to clinical outcomes, the FOA emphasizes a development strategy that can make GBM trials more informative, reduce uncertainty in go/no-go decisions, and ultimately accelerate progress toward more effective treatments for adult brain tumor patients.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is the Limited Competition Adult Brain Tumor Consortium (ABTC) (UM1) funding opportunity, identified as RFA-CA-13-501.
Which agency is offering this opportunity?
This is a National Cancer Institute (NCI), National Institutes of Health cooperative agreement.
What is the main purpose of the award?
The purpose is to continue and strengthen NCI's established clinical trials program focused on adult brain tumors, with a particular emphasis on glioblastoma multiforme (GBM). The intent is to sustain an existing, NCI-supported clinical trials network that can rapidly evaluate promising anticancer therapies for adults with GBM and related brain tumors.
Is this opportunity meant to create a brand-new consortium?
No. The intent is not to create a new consortium. It is designed to sustain an existing NCI-supported clinical trials network.
What type of funding mechanism is used (grant vs. cooperative agreement)?
The funding instrument is a cooperative agreement (UM1). This structure includes substantial NCI involvement in planning, coordination, and oversight.
What does "substantial NCI involvement" mean in this context?
Because it is a cooperative agreement (UM1), NCI is expected to play an active role in the planning, coordination, and oversight of the work, reflecting the complexity and national importance of conducting early-stage therapeutic trials in adults with GBM and related brain tumors.
What clinical trial phases are prioritized under this FOA?
The announcement emphasizes early phase clinical development, specifically Phase I and Phase II trials in adults with GBM.
What kinds of outcomes are Phase I and Phase II studies expected to address here?
The trials are expected to help determine safety, dosing, preliminary efficacy, and feasibility, while producing information that supports decisions about which interventions should move forward in the development pipeline.
What disease area is the central focus?
The central focus is adult brain tumors, with particular emphasis on glioblastoma multiforme (GBM).
Are other brain tumors included besides GBM?
Yes. While GBM is emphasized, the consortium is also described as evaluating therapies for adults with GBM and related brain tumors.
What is expected regarding translational research?
The FOA pushes the consortium to expand and deepen translational research capabilities by going beyond standard clinical endpoints and incorporating studies that clarify how a drug behaves in the body and how it interacts with intended biological targets.
What does the FOA say about pharmacokinetics (PK)?
There is a stronger emphasis on understanding pharmacokinetics, described as how the drug is absorbed, distributed, metabolized, and eliminated.
What does the FOA say about pharmacodynamics (PD)?
There is a stronger emphasis on understanding pharmacodynamics, described as what biological effects the drug produces, including whether it hits the intended target.
How are biospecimens used under this opportunity?
The FOA highlights the need to characterize drug effects on relevant cellular and molecular targets using appropriate biospecimens and to integrate laboratory and biomarker findings with clinical data.
What is the broader scientific goal of the PK/PD and biomarker emphasis?
The larger goal is to improve understanding of the biological and molecular factors that influence response in GBM, which can help refine patient selection, optimize dosing strategies, and guide rational combination therapies.
Why is this called a "limited competition"?
Eligibility is tightly restricted. Only the current awardee(s) of the Adult Brain Tumor Consortium previously funded under RFA-CA-08-504 may apply.
How many awards are expected to be made?
Only one award is expected to be made.
Are foreign institutions eligible to apply?
No. Foreign institutions are not eligible.
Are foreign components allowed under NIH policy?
No. Foreign components, as defined by NIH policy, are not allowed.
Where must the supported infrastructure and trial operations be based?
Based on the restriction against foreign institutions and foreign components, the supported infrastructure and trial operations must be based in the United States.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.395 (Cancer Treatment Research).
How is the opportunity categorized in terms of funding area?
It is categorized as discretionary funding under a health-related activity area.
When was the FOA posted?
The FOA was posted on June 19, 2013.
What was the application due date?
The application due date was September 16, 2013.
When was the archive date?
The archive date was October 17, 2013.
How much total funding is estimated for this opportunity?
The estimated total funding amount is $2,000,000.
What is the award ceiling?
The award ceiling is $2,000,000.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement.
What operational expectations are placed on the consortium?
The consortium is expected to identify agents with signs of antitumor activity in a way that is clinically rigorous, operationally efficient, and well-coordinated across participating sites.
What kinds of deliverables does NCI appear to want from ABTC under this FOA?
The FOA emphasizes well-run Phase I and II studies that identify promising therapies, along with mechanistic and biomarker-driven insights showing whether drugs reach and affect their targets in patients, supported by comprehensive PK/PD work and biospecimen-based target analyses linked to clinical outcomes.
How does this FOA aim to improve decision-making in GBM therapy development?
By requiring integrated PK/PD, biospecimen-based target analyses, and linkage of biomarker findings to clinical outcomes, the FOA emphasizes a strategy intended to make trials more informative, reduce uncertainty in go/no-go decisions, and accelerate progress toward more effective treatments for adult brain tumor patients.
Browse more opportunities from the same category: Education Health
Next opportunity: Limited Competition Pediatric Brain Tumor Consortium (UM1)
Previous opportunity: Cooperative Ecosystem Studies Unit, Colorado Plateau CESU
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 13 501
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 13 501) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition Pediatric Brain Tumor Consortium (UM1) Apply for RFA CA 13 502 Funding Number: RFA CA 13 502 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,590,000 |
| Clinical Trials and Interventional Studies of Non Pharmacological Approaches to Managing Pain and Co Morbid Conditions in U.S. Military Personnel, Veterans, and their Families (R01) Apply for RFA AT 14 003 Funding Number: RFA AT 14 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Pilot and Feasibility Studies of Non Pharmacological Approaches to Managing Pain and Co Morbid Conditions in U.S. Military Personnel, Veterans, and their Families (R34) Apply for RFA AT 14 004 Funding Number: RFA AT 14 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Health Services and Observational Studies of Non Pharmacological Approaches to Managing Pain and Co Morbid Conditions in U.S. Military Personnel, Veterans, and their Families (R01) Apply for RFA AT 14 005 Funding Number: RFA AT 14 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Program Project Grant Applications (P01) Apply for PAR 13 259 Funding Number: PAR 13 259 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Synergizing Omic and Symptom Science (R15) Apply for PA 13 265 Funding Number: PA 13 265 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Synergizing Omic and Symptom Science (R01) Apply for PA 13 264 Funding Number: PA 13 264 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Grand Opportunity in Medications Development for Substance Use Disorders (U01) Apply for PAR 13 270 Funding Number: PAR 13 270 Agency: National Institutes of Health Category: Education Health Funding Amount: $5,000,000 |
| Revision Applications to Promote Collaborative Research on Addiction at NIH (CRAN) Comorbidity Related Research (R01) Apply for RFA DA 14 014 Funding Number: RFA DA 14 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Administrative Supplements to Promote Collaborative Research on Addiction at NIH (CRAN) Comorbidity Related Research (Admin Supp) Apply for PA 13 275 Funding Number: PA 13 275 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Abuse Resistant and Abuse Deterrent Formulations and Devices to Avoid the Abuse, Misuse and Diversion of Prescription Opioids by Patients (SBIR)(R43/R44) Apply for RFA DA 14 013 Funding Number: RFA DA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PAR 13 282 Funding Number: PAR 13 282 Agency: National Institutes of Health Category: Education Health Funding Amount: $175,000 |
| NLM Career Development Award in Biomedical Informatics (K01) Apply for PAR 13 284 Funding Number: PAR 13 284 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Building Evidence Effective Palliative/End of Life Care Interventions (R01) Apply for PAR 13 289 Funding Number: PAR 13 289 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Express Research Grants in Biomedical Informatics (R01) Apply for PAR 13 300 Funding Number: PAR 13 300 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Advanced Development of Informatics Technology (U24) Apply for PAR 13 294 Funding Number: PAR 13 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Revisions to P01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P01) Apply for PAR 13 297 Funding Number: PAR 13 297 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions to P50 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P50) Apply for PAR 13 298 Funding Number: PAR 13 298 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P01) Apply for PAR 13 317 Funding Number: PAR 13 317 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50) Apply for PAR 13 318 Funding Number: PAR 13 318 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 13 501", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.